18 April 2018

Scancell Holdings plc

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, has raised £7.5 million through an institutional placing of shares.

LGB Corporate Finance worked closely with the company and its corporate broker, Panmure Gordon, to extend distribution of the issue to a number of wealth management, family office and private investors.

The proceeds of the placing will be used to commence scheduled trials of a vaccine addressing late stage melanoma, support the Cancer Research UK development of the company vaccine against non-small-cell lung carcinoma, commence a first in-human study in patients with triple-negative breast cancer, further the company’s collaboration with BioNTech and initiate a pre-clinical development programme for oesophageal, gastric, pancreatic and colorectal cancers.  These projects demonstrate the broadening scope of the company’s business and its collaborations with tier-1 counterparties in the immuno oncology sector.

Recent Articles

26 May 2020

BoE: Negative interest rates not ruled out

Andrew Boyle, CEO of LGB & Co. Limited, contributed to an article for Mortgage Introducer Bank of England Governor Andrew Bailey's refusal to rule out the prospect of negative interest rates.

 

Read more

News & Insights

4 May 2020

Small cap movers: Coronavirus crisis shines a light on small-cap pharma

Ivan Sedgwick, Investments Director at LGB & Co. Limited, contributed to an article for ProActive Investors on small-cap pharmaceutical companies in the Coronavirus limelight.

Read more

News & Insights

30 April 2020

What impact is COVID-19 having on stocks?

Ivan Sedgwick, Director of Investments at LGB & Co, spoke to BLM to find out about the current outlook for the AIM market.

 

Read more

News & Insights